false
0000890821
0000890821
2025-01-30
2025-01-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
January
30, 2025
Date
of Report (Date of earliest event reported)
Enveric
Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38286 |
|
95-4484725 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
Enveric
Biosciences, Inc.
4851
Tamiami Trail N, Suite 200
Naples,
FL 34103
(Address
of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code: (239) 302-1707
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, par value $0.01 per share |
|
ENVB |
|
The
Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry Into a Material Definitive Agreement.
Securities
Purchase Agreement
On
January 30, 2025, Enveric Biosciences, Inc. (the “Company”) commenced a best efforts public offering (the “Offering”)
of an aggregate of (i) 1,229,330 shares (the “Shares”) of common stock, par value $0.01 per share (“Common Stock”),
of the Company, (ii) 437,336 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 437,336 shares of Common Stock (the
“Pre-Funded Warrant Shares”), (iii) 1,666,666 Series A warrants (the “Series A Warrants”) to purchase 1,666,666
shares of Common Stock (the “Series A Warrant Shares”), and (iv) 1,666,666 Series B warrants (the “Series B Warrants,”
and together with the Series A Warrants, the “Warrants”) to purchase 1,666,666 shares of Common Stock (the “Series
B Warrant Shares”). Each Share or Pre-Funded Warrant was sold together with one Series A Warrant to purchase one share of Common
Stock and one Series B Warrant to purchase one share of Common Stock. The offering price for each Share and accompanying Warrants was
$3.00, and the offering price for each Pre-Funded Warrant and accompanying Warrants was $2.9999. The Pre-Funded Warrants have an exercise
price of $0.0001 per share, are exercisable immediately and will expire when exercised in full. Each Warrant has an exercise price of
$3.00 per share and will be exercisable immediately upon issuance (“Initial Exercise Date”). The Series A Warrants expire
on the five-year anniversary of the Initial Exercise Date. The Series B Warrants expire on the 18-month anniversary of the Initial Exercise
Date.
The
Offering closed on February 3, 2025. The net proceeds of the Offering, after deducting the fees and expenses of the Placement Agent (as
defined below), described in more detail below, and other offering expenses payable by the Company, but excluding the net proceeds, if
any, from the exercise of the Warrants, is approximately $4.3 million. The Company intends to use the net proceeds from the Offering
for working capital, EB-003 development, and general corporate purposes.
In
connection with the Offering, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a
certain institutional investor. Pursuant to the Purchase Agreement, the Company agreed not to issue, enter into any agreement to issue
or announce the issuance or proposed issuance of any shares of Common Stock or any securities convertible into or exercisable or exchangeable
for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement thereto for 60 days after
the closing date of the Offering, subject to certain exceptions. In addition, the Company has agreed not to effect or enter into an agreement
to effect any issuance of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock involving
a variable rate transaction (as defined in the Purchase Agreement) until the one-year anniversary of the closing date of the Offering,
subject to an exception.
The
Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company and the purchasers, including for liabilities arising under the Securities Act of 1933, as amended (the “Securities
Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in
the Purchase Agreement were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the
parties to such agreements and may be subject to limitations agreed upon by the contracting parties.
A
holder will not have the right to exercise any portion of the Warrants or Pre-Funded Warrants if the holder (together with its affiliates)
would beneficially own in excess of 4.99% or 9.99%, as applicable, of the number of shares of Common Stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants or the Pre-Funded
Warrants, respectively.
Pursuant
to an engagement agreement, as amended, (the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement
Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate
gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds received in the Offering,
(iii) a non-accountable expense allowance of $25,000, (iv) reimbursement of up to $100,000 for legal fees and expenses and other out
of pocket expenses and (v) up to $15,950 for the clearing expenses.
Also
pursuant to the Engagement Agreement, the Company, in connection with the Offering, agreed to issue to the Placement Agent or its designees
warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 116,666 shares of Common Stock (the “Placement
Agent Warrant Shares”) (which represents 7.0% of the Shares and Pre-Funded Warrants sold in the Offering). The Placement Agent
Warrants have an exercise price of $3.75 per share (which represents 125% of the public offering price per Share and accompanying Warrants),
expire on January 30, 2030, and are exercisable following the Initial Exercise Date.
The
Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Series A Warrants, the Series A Warrant Shares, Series B Warrants,
the Series B Warrant Shares, the Placement Agent Warrants, and the Placement Agent Warrant Shares were offered by the Company pursuant
to a Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission on January 14, 2025, as amended
(including the prospectus forming a part of such Registration Statement), under the Securities Act (File No. 333-284277), and declared
effective by the SEC on January 30, 2025.
The
foregoing descriptions of the Purchase Agreement, the Pre-Funded Warrants, the Series A Warrants, the Series B Warrants, and the Placement
Agent Warrants are not complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement,
the form of Pre-Funded Warrant, the form of Series A Warrant, the form of Series B Warrant, and the form of Placement Agent Warrant,
copies of which are filed as Exhibits 10.1, 4.1, 4.2, 4.3, and 4.4, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.
Item
8.01 Other Events.
Press
Release
On
January 30, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of such press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
On
February 3, 2025, the Company issued a press release announcing the closing of the Offering. A copy of such press release is attached
as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number |
|
Description |
| 4.1 |
|
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.14 of the Company’s Registration Statement on Form S-1/A, filed with the Commission on January 30, 2025) |
| 4.2 |
|
Form of Series A Warrant (incorporated by reference to Exhibit 4.15 of the Company’s Registration Statement on Form S-1/A, filed with the Commission on January 30, 2025) |
| 4.3 |
|
Form of Series B Warrant (incorporated by reference to Exhibit 4.16 of the Company’s Registration Statement on Form S-1/A, filed with the Commission on January 30, 2025) |
| 4.4 |
|
Form of Placement Agent Warrants (incorporated by reference to Exhibit 4.17 of the Company’s Registration Statement on Form S-1/A, filed with the Commission on January 30, 2025) |
| 10.1+ |
|
Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.33 of the Company’s Registration Statement on Form S-1/A, filed with the Commission on January 30, 2025) |
| 99.1 |
|
Press release, dated January 30, 2025 |
| 99.2 |
|
Press release, dated February 3, 2025 |
| 104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL) |
+
Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental
copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
February 3, 2025 |
ENVERIC
BIOSCIENCES, INC. |
| |
|
|
| |
By: |
/s/
Joseph Tucker |
| |
|
Joseph
Tucker |
| |
|
Chief
Executive Officer |
Exhibit 99.1
Enveric
Biosciences Announces Pricing of $5 Million Public Offering
CAMBRIDGE,
Mass., January 30, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology
company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression,
and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or
common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,666 shares of common stock and Series B warrants
to purchase up to 1,666,666 shares of common stock, at a combined public offering price of $3.00 per share (or per common stock equivalent
in lieu thereof) and accompanying warrants. The warrants will have an exercise price of $3.00 per share and will be exercisable immediately.
The Series A warrants will expire five years from the date of issuance and the Series B warrants will expire eighteen months from the
date of issuance. The closing of the offering is expected to occur on or about February 3, 2025, subject to the satisfaction of customary
closing conditions.
H.C.
Wainwright & Co. is acting as the exclusive placement agent for the offering.
The
gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company,
are expected to be approximately $5 million. The Company intends to use the net proceeds from this offering for product development,
working capital and general corporate purposes.
The
securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-284277), which was declared
effective by the Securities and Exchange Commission (the “SEC”) on January 30, 2025. The offering is being made only by means
of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the
offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website
at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York,
NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Enveric Biosciences
Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics
for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™,
which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications,
Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates.. Enveric’s lead molecule, EB-003, is
a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering
from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of
neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing
non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary,
AB Canada. For more information, please visit www.enveric.com.
Forward-Looking
Statements
This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,”
“schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates”
or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds
therefrom. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors,
including, but not limited to, the ability of Enveric to: successfully outlicense patented Psybrary™ drug candidates to third-party
licensees; negotiate and finalize definitive agreements based on any of its out-licensing term sheets and for licensees to perform pursuant
to the terms thereof; finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs;
achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential
products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic
candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development
and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and
nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products,
including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets;
continue as a going concern; and manage its future growth effectively.
Contacts
Investor
Relations
Tiberend
Strategic Advisors, Inc.
David
Irish
(231)
632-0002
dirish@tiberend.com
Media
Relations
Tiberend
Strategic Advisors, Inc.
Casey
McDonald
(646)
577-8520
cmcdonald@tiberend.com
Exhibit
99.2
Enveric
Biosciences Announces Closing of $5 Million Public Offering
CAMBRIDGE,
Mass., February 3, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology
company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression,
and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 shares
of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,666 shares of common stock
and Series B warrants to purchase up to 1,666,666 shares of common stock, at a combined public offering price of $3.00 per share (or
per common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $3.00 per share and are
exercisable immediately. The Series A warrants will expire five years from the date of issuance and the Series B warrants will expire
eighteen months from the date of issuance.
H.C.
Wainwright & Co. acted as the exclusive placement agent for the offering.
The
gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company,
were approximately $5 million. The Company intends to use the net proceeds from this offering for product development, working capital
and general corporate purposes.
The
securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-284277), which was declared effective
by the Securities and Exchange Commission (the “SEC”) on January 30, 2025. The offering was made only by means of a prospectus
forming part of the effective registration statement relating to the offering. A final prospectus relating to the offering has been filed
with the SEC. Electronic copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov and may also
be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711
or e-mail at placements@hcwco.com.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Enveric Biosciences
Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics
for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™,
which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications,
Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is
a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering
from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of
neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing
non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary,
AB Canada. For more information, please visit www.enveric.com.
Forward-Looking
Statements
This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,”
“schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates”
or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including, but not limited to, the ability of Enveric to: successfully outlicense patented
Psybrary™ drug candidates to third-party licensees; negotiate and finalize definitive agreements based on any of its out-licensing
term sheets and for licensees to perform pursuant to the terms thereof; finalize and submit its IND filing to the U.S. Food and Drug
Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays
in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or
maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market
potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture
of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure
and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to
capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
Contacts
Investor
Relations
Tiberend
Strategic Advisors, Inc.
David
Irish
(231)
632-0002
dirish@tiberend.com
Media
Relations
Tiberend
Strategic Advisors, Inc.
Casey
McDonald
(646)
577-8520
cmcdonald@tiberend.com
v3.25.0.1
Cover
|
Jan. 30, 2025 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jan. 30, 2025
|
| Entity File Number |
001-38286
|
| Entity Registrant Name |
Enveric
Biosciences, Inc.
|
| Entity Central Index Key |
0000890821
|
| Entity Tax Identification Number |
95-4484725
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
Enveric
Biosciences, Inc.
|
| Entity Address, Address Line Two |
4851
Tamiami Trail N
|
| Entity Address, Address Line Three |
Suite 200
|
| Entity Address, City or Town |
Naples
|
| Entity Address, State or Province |
FL
|
| Entity Address, Postal Zip Code |
34103
|
| City Area Code |
(239)
|
| Local Phone Number |
302-1707
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
stock, par value $0.01 per share
|
| Trading Symbol |
ENVB
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 3 such as an Office Park
| Name: |
dei_EntityAddressAddressLine3 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Jan 2025 to Feb 2025
Enveric Biosciences (NASDAQ:ENVB)
Historical Stock Chart
From Feb 2024 to Feb 2025
